DB
HGEN

Dmitry Balyasny’s HUMANIGEN, INC. HGEN Stock Holding History

Dmitry Balyasny’s Portfolio HGEN Stock Details HGEN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-11,362
Closed -$217K – 2501
2021
Q1 		$217K Buy
+11,362
New +$207K ﹤0.01% 1566

Other funds holding HGEN

VCM
Valiant Capital Management San Francisco, California $2.48B AUM 57.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
M
Murchinson Toronto, Ontario, Canada $725M AUM 82.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TI
Think Investments San Francisco, California $847M AUM 88.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Dmitry Balyasny's HGEN Position: Q2 2021 in Review

Dmitry Balyasny sold out of HUMANIGEN, INC. (HGEN) in Q2 2021, closing a stake of 11,362 shares — an estimated $217K sold.

Dmitry Balyasny first reported a position in HGEN in Q1 2021 and held it in 1 quarter. The position peaked at $217K in Q1 2021. 92 funds tracked by Wall St. Rank hold HGEN as of Q2 2021.

  • Dmitry Balyasny reported no remaining HUMANIGEN, INC. position as of Q2 2021 after selling out during the quarter.
  • Dmitry Balyasny sold 11,362 HUMANIGEN, INC. shares in Q2 2021, an estimated $217K.
  • Dmitry Balyasny first reported a position in HUMANIGEN, INC. in Q1 2021 and held it in 1 quarter.
  • Dmitry Balyasny's HUMANIGEN, INC. position peaked at $217K in Q1 2021.
  • 92 funds tracked by Wall St. Rank held HUMANIGEN, INC. as of Q2 2021.

Based on Balyasny Asset Management's 13F filing for Q2 2021, filed 16 Aug 2021.